Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Samsung Biologics launches development platforms for enhanced therapeutic efficacy 2024-09-25 19:00
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP 2024-09-24 21:00
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners 2024-09-24 21:00
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery 2024-09-24 20:00
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024 2024-09-23 17:40
WuXi Biologics Included in Hang Seng ESG 50 Index 2024-09-23 17:30
Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease Treatments 2024-09-23 15:06
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting 2024-09-20 20:30
Kangpu Completed Bridging Clinical Study of KPG-818 in China 2024-09-20 20:00
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001 2024-09-20 16:28
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024 2024-09-19 20:30
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC 2024-09-19 09:00
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI 2024-09-18 21:30
Bloomage 2024 Mid-Year Report: Driving Growth Through Strategic Transformation to a Solutions Provider 2024-09-18 21:00
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress 2024-09-18 18:18
Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI 2024-09-18 10:06
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics 2024-09-17 15:47
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024 2024-09-17 00:01
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment 2024-09-16 19:00
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024 2024-09-16 18:00
1 5 6 7 8 9 165